Skip to main content
Top

05-16-2018 | Diet | Article

Intake of polyunsaturated fatty acids and risk of preclinical and clinical type 1 diabetes in children—a systematic review and meta-analysis

Journal: European Journal of Clinical Nutrition

Authors: Xinliang Liu, Yu Zhang, Hongyan Wu, Ping Zhu, Xianyang Mo, Xiaosong Ma, Jie Ying

Publisher: Nature Publishing Group UK

Abstract

Background/objectives

The association between the intake of polyunsaturated fatty acids (PUFAs) and the risk of preclinical and clinical type 1 diabetes (T1D) in children has generated conflicting results. Thus, we aimed to evaluate the definite effects of PUFAs on the risk of preclinical and clinical T1D.

Subjects/methods

Three databases were systematically searched up to July 18, 2017 to identify relevant observational studies, without language restriction. Any study included should report the risk of preclinical or clinical T1D in children with PUFAs supplementation compared with the controls, and report relative risks (RRs) or odds ratios (ORs) or provide data for estimation. Pooled RRs (or ORs) with 95% confidence intervals (CI) were calculated using random-effects models irrespective of statistical heterogeneity assessed by I2 statistic.

Results

We identified seven studies (three prospective cohort studies and four case-control studies) on PUFAs intake during pregnancy or during early life in children. The pooled RR between the risk of preclinical T1D and n-3 PUFAs supplementation against controls was 0.98 (95%CI, 0.85–1.13), with no heterogeneity. The results were similar after the intake during pregnancy, but not during early life in children (pooled RR, 0.45; 95%CI, 0.21–0.96; P = 0.039). N-3 PUFAs supplementation was not associated with a significant reduction in the risk of clinical T1D in children (pooled RR, 0.87; 95%CI, 0.71–1.08), with substantial heterogeneity(I2 = 64.7%). No association was also found between n-6 PUFAs intake and the risk of preclinical (1.07; 0.97–1.017) or clinical T1D (1.05; 0.92–1.20) in children.

Conclusions

The result of the meta-analysis does not support that n-3 or n-6 PUFAs supplementation in children affects the overall risk of preclinical or clinical T1D. However, n-3 PUFAs intake in early life might reduce the risk of preclinical T1D. Therefore, this finding should be verified by more and well-designed prospective research in the future.
Literature
1.
Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Prim. 2017;3:17016. CrossRef
2.
Tao Z, Shi A, Zhao J. Epidemiological perspectives of diabetes. Cell Biochem Biophys. 2015;73:181–185. CrossRef
3.
Shao L, Feng B, Zhang Y, Zhou H, Ji W, Min W. The role of adipose-derived inflammatory cytokines in type 1 diabetes. Adipocyte. 2016;5:270–4. CrossRef
4.
Cvetkovic I, Al-Abed Y, Miljkovic D, Maksimovic-Ivanic D, Roth J, Bacher M, et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology. 2005;146:2942–51. CrossRef
5.
Marée AF, Komba M, Dyck C, Łabecki M, Finegood DT, Edelstein-Keshet L. Quantifying macrophage defects in type 1 diabetes. J Theor Biol. 2005;233:533–51. CrossRef
6.
Fatima N, Faisal SM, Zubair S, Ajmal M, Siddiqui SS, Moin S, et al. Role of pro-inflammatory cytokines and biochemical markers in the pathogenesis of type 1 diabetes: correlation with age and glycemic condition in diabetic human subjects. PLoS ONE. 2016;11:e0161548. CrossRef
7.
Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016;387:2331–9. CrossRef
8.
Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet. 2016;387:2340–8. CrossRef
9.
Butalia S, Kaplan GG, Khokhar B, Rabi DM. Environmental risk factors and type 1 diabetes: past, present, and future. Can J Diabetes. 2016;40:586–93. CrossRef
10.
Rodriguez-Calvo T, Sabouri S, Anquetil F, von HMG. The viral paradigm in type 1 diabetes: who are the main suspects. Autoimmun Rev. 2016;15:964–9. CrossRef
11.
Virtanen SM. Dietary factors in the development of type 1 diabetes. Pediatr Diabetes. 2016;17 Suppl 22:49–55. CrossRef
12.
Dahlquist GG, Blom LG, Persson LA, Sandström AI, Wall SG. Dietary factors and the risk of developing insulin dependent diabetes in childhood. BMJ. 1990;300:1302–6. CrossRef
13.
Poudel RR, Shrestha D. Breastfeeding for diabetes prevention. J Pak Med Assoc. 2016;66:S88–90. PubMed
14.
Pieścik-Lech M, Chmielewska A, Shamir R, Szajewska H. Systematic review: early infant feeding and the risk of type 1 diabetes. J Pediatr Gastroenterol Nutr. 2017;64:454–9. CrossRef
15.
Cadario F, Savastio S, Rizzo AM, Carrera D, Bona G, Ricordi C. Can type 1 diabetes progression be halted? Possible role of high dose vitamin D and omega 3 fatty acids. Eur Rev Med Pharmacol Sci. 2017;21:1604–9. PubMed
16.
Granfors M, Augustin H, Ludvigsson J, Brekke HK. No association between use of multivitamin supplement containing vitamin D during pregnancy and risk of type 1 diabetes in the child. Pediatr Diabetes. 2016;17:525–30. CrossRef
17.
Jacobsen R, Thorsen SU, Cohen AS, Lundqvist M, Frederiksen P, Pipper CB, et al. Neonatal vitamin D status is not associated with later risk of type 1 diabetes: results from two large Danish population-based studies. Diabetologia. 2016;59:1871–81. CrossRef
18.
Dong JY, Zhang WG, Chen JJ, Zhang ZL, Han SF, Qin LQ. Vitamin D intake and risk of type 1 diabetes: a meta-analysis of observational studies. Nutrients. 2013;5:3551–62. CrossRef
19.
Virtanen SM, Niinistö S, Nevalainen J, Salminen I, Takkinen HM, Kääriä S, et al. Serum fatty acids and risk of advanced beta-cell autoimmunity: a nested case-control study among children with HLA-conferred susceptibility to type I diabetes. Eur J Clin Nutr. 2010;64:792–9. CrossRef
20.
Sørensen IM, Joner G, Jenum PA, Eskild A, Stene LC. Serum long chain n-3 fatty acids (EPA and DHA) in the pregnant mother are independent of risk of type 1 diabetes in the offspring. Diabetes Metab Res Rev. 2012;28:431–8. CrossRef
21.
Stene LC, Joner G. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr. 2003;78:1128–34. CrossRef
22.
Norris JM, Yin X, Lamb MM, Barriga K, Seifert J, Hoffman M, et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA. 2007;298:1420–8. CrossRef
23.
Niinistö S, Takkinen HM, Uusitalo L, Rautanen J, Nevalainen J, Kenward MG, et al. Maternal dietary fatty acid intake during pregnancy and the risk of preclinical and clinical type 1 diabetes in the offspring. Br J Nutr. 2014;111:895–903. CrossRef
24.
Fronczak CM, Barón AE, Chase HP, Ross C, Brady HL, Hoffman M, et al. In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care. 2003;26:3237–42. CrossRef
25.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. CrossRef
26.
Lu RJ, Zhu SM, Tang FL, Zhu XS, Fan ZD, Wang GL, et al. Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis. Eur J Clin Nutr. 2017;71:683–93. CrossRef
27.
Erickson J, Sadeghirad B, Lytvyn L, Slavin J, Johnston BC. The scientific basis of guideline recommendations on sugar intake: a systematic review. Ann Intern Med. 2017;166:257–67. CrossRef
28.
Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychol Methods. 2001;6:203–17. CrossRef
29.
Norris JM, Kroehl M, Fingerlin TE, Frederiksen BN, Seifert J, Wong R, et al. Erythrocyte membrane docosapentaenoic acid levels are associated with islet autoimmunity: the Diabetes Autoimmunity Study in the young. Diabetologia. 2014;57:295–304. CrossRef
30.
Niinistö S, Takkinen HM, Uusitalo L, Rautanen J, Vainio N, Ahonen S, et al. Maternal intake of fatty acids and their food sources during lactation and the risk of preclinical and clinical type 1 diabetes in the offspring. Acta Diabetol. 2015;52:763–72. CrossRef
31.
Stene LC, Ulriksen J, Magnus P, Joner G. Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia. 2000;43:1093–8. CrossRef
32.
Miller MR, Yin X, Seifert J, Clare-Salzler M, Eisenbarth GS, Rewers M, et al. Erythrocyte membrane omega-3 fatty acid levels and omega-3 fatty acid intake are not associated with conversion to type 1 diabetes in children with islet autoimmunity: the Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes. 2011;12:669–75. CrossRef
33.
Jacobsen R, Hypponen E, Sørensen TI, Vaag AA, Heitmann BL. Gestational and early infancy exposure to margarine fortified with vitamin D through a National Danish Programme and the risk of type 1 diabetes: the D-Tect Study. PLoS ONE. 2015;10:e0128631. CrossRef
34.
Sørensen IM, Joner G, Jenum PA, Eskild A, Torjesen PA, Stene LC. Maternal serum levels of 25-hydroxy-vitamin D during pregnancy and risk of type 1 diabetes in the offspring. Diabetes. 2012;61:175–8. CrossRef
35.
Niinistö S, Takkinen HM, Erlund I, Ahonen S, Toppari J, Ilonen J, et al. Fatty acid status in infancy is associated with the risk of type 1 diabetes-associated autoimmunity. Diabetologia. 2017;60:1223–33. CrossRef
36.
Raheja BS, Sadikot SM, Phatak RB, Rao MB. Significance of the N-6/N-3 ratio for insulin action in diabetes. Ann N Y Acad Sci. 1993;683:258–71. CrossRef
37.
Borch-Johnsen K, Joner G, Mandrup-Poulsen T, Christy M, Zachau-Christiansen B, Kastrup K, et al. Relation between breast-feeding and incidence rates of insulin-dependent diabetes mellitus. A hypothesis. Lancet. 1984;2:1083–6. CrossRef
38.
Knip M, Virtanen SM, Akerblom HK. Infant feeding and the risk of type 1 diabetes. Am J Clin Nutr. 2010;91:1506S–1513S. CrossRef
39.
Houghteling PD, Walker WA. Why is initial bacterial colonization of the intestine important to infants’ and children’s health. J Pediatr Gastroenterol Nutr. 2015;60:294–307. CrossRef

Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video